Blog

2024 Equity in Access Research Program Grantees of The Leukemia and Lymphoma Society

Photo taken from The Leukemia and Lymphoma Society/X

Jul 13, 2024, 05:22

2024 Equity in Access Research Program Grantees of The Leukemia and Lymphoma Society

The Leukemia and Lymphoma Society shared on X:

“Let’s applaud our 2024 Equity in Access Research Program Grantees! We’ve awarded nearly $6.5M to address barriers to blood cancer treatment & care that may lead to better health outcomes – supported by Royalty Pharma & Astra Zeneca. Discover more about our grantees & their work.”

Source: The Leukemia and Lymphoma Society/X

AstraZeneca blood cancer care blood cancer treatment cancer cancer care barriers Cancer Equity cancer research funding cancer research grantees Cancer Treatment Access Equity in Access Research Program health outcomes Leukemia and Lymphoma Society OncoDaily Oncology Royalty Pharma

Oncologist Near Me - Vivek Subbiah: Pionner of Precision Oncology

Monica Bertagnolli is ending her tenure as NIH director

NEW PAPER ALERT: Efficacy of CDK4/6 Inhibitors and Endocrine Therapy in HR+/HER2- Advanced Breast Cancer by PAM50 Subtype: SOLTI-1801 CDK-PREDICT Results

Oncologist Near Me – Fabrice André: Leading Expert in Breast Cancer

Funding Impactful Cancer Research That Might Otherwise Go Unsupported: Ryan Schoenfeld on the Secret Behind Mark Foundation’s Success